omidenepag
Selected indexed studies
- Omidenepag Isopropyl. (Am J Health Syst Pharm, 2023) [PMID:36545781]
- Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. (Drugs Today (Barc), 2019) [PMID:31250842]
- Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. (Drugs, 2018) [PMID:30465134]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Omidenepag Isopropyl. (2023) pubmed
- Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. (2019) pubmed
- Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval. (2018) pubmed
- Neuroprotective effect of omidenepag on excitotoxic retinal ganglion cell death regulating COX-2-EP2-cAMP-PKA/Epac pathway via Neuron-Glia interaction. (2024) pubmed
- Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis. (2025) pubmed
- Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis. (2023) pubmed
- Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension. (2022) pubmed
- Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug. (2024) pubmed
- Periocular Adverse Reactions to Omidenepag Isopropyl. (2022) pubmed
- Effectiveness and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution in Treatment-Naive Patients With Primary Open Angle Glaucoma: A Prospective Multicenter Phase IV Study. (2025) pubmed